公开(公告)号：US20170298363A1

公开(公告)日：2017-10-19

申请号：US15511833

申请日：2015-09-18

Applicant: GENOMATICA, INC

Inventor： Priti Pharkya ,  Anthony Burgard ,  Eric Roland Nunez Van Name

IPC: C12N15/52 ,  C12N9/12 ,  C12P7/18 ,  C12P5/02 ,  C12N9/88 ,  C12P7/40 ,  C12P7/04

CPC classification number: C12N15/52 ,  C12N9/1205 ,  C12N9/88 ,  C12P5/026 ,  C12P7/04 ,  C12P7/18 ,  C12P7/40 ,  C12P7/42 ,  C12Y207/0104 ,  C12Y401/02009 ,  C12Y401/02022 ,  Y02E50/343

Abstract: The invention provides non-natural microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing carbon flux through acetyl-CoA, or oxaloacetate and acetyl-CoA. Embodiments of the invention include microbial organisms having a pathway to acetyl-CoA and oxaloacetate that includes phosphoketolase (a PK pathway). The organisms also have either (i) a genetic modification that enhances the activity of the non-phosphotransferase system (non-PTS) for sugar uptake, and/or (ii) a genetic modification(s) to the organism's electron transport chain (ETC) that enhances efficiency of ATP production, that enhances availability of reducing equivalents or both. The microbial organisms can optionally include (iii) a genetic modification that maintains, attenuates, or eliminates the activity of a phosphotransferase system (PTS) for sugar uptake. The enhanced carbon flux through acetyl-CoA and oxaloacetate can be used for production of a bioderived compound, and the microbial organisms can further include a pathway capable of producing the bioderived compound.

公开(公告)号：US20230126921A1

公开(公告)日：2023-04-27

申请号：US17843589

申请日：2022-06-17

Applicant: Genomatica, Inc.

Inventor： Priti Pharkya ,  Anthony P. Burgard ,  Eric Roland Nunez Van Name

IPC: C12N15/52 ,  C12N9/88 ,  C12P7/18 ,  C12P7/42 ,  C12N9/12 ,  C12P5/02 ,  C12P7/04 ,  C12P7/40

Abstract: The invention provides non-natural microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing carbon flux through acetyl-CoA, or oxaloacetate and acetyl-CoA. Embodiments of the invention include microbial organisms having a pathway to acetyl-CoA and oxaloacetate that includes phosphoketolase (a PK pathway). The organisms also have either (i) a genetic modification that enhances the activity of the non-phosphotransferase system (non-PTS) for sugar uptake, and/or (ii) a genetic modification(s) to the organism's electron transport chain (ETC) that enhances efficiency of ATP production, that enhances availability of reducing equivalents or both. The microbial organisms can optionally include (iii) a genetic modification that maintains, attenuates, or eliminates the activity of a phosphotransferase system (PTS) for sugar uptake. The enhanced carbon flux through acetyl-CoA and oxaloacetate can be used for production of a bioderived compound, and the microbial organisms can further include a pathway capable of producing the bioderived compound.